PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS)’s share price hit a new 52-week low on Monday . The company traded as low as $4.72 and last traded at $4.74, with a volume of 24692 shares. The stock had previously closed at $5.01.
PHAS has been the topic of a number of research analyst reports. Citigroup initiated coverage on PhaseBio Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $18.00 target price on the stock. Stifel Nicolaus initiated coverage on PhaseBio Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $14.00 target price on the stock. Finally, Cowen initiated coverage on shares of PhaseBio Pharmaceuticals in a report on Monday. They issued an “outperform” rating on the stock.
In related news, major shareholder Venture Advisors Iii Hatteras purchased 300,000 shares of the stock in a transaction that occurred on Monday, October 22nd. The shares were bought at an average price of $5.00 per share, with a total value of $1,500,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Linda Tufts purchased 20,000 shares of the stock in a transaction that occurred on Monday, October 22nd. The stock was bought at an average cost of $5.00 per share, for a total transaction of $100,000.00. The disclosure for this purchase can be found here.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/11/12/phasebio-pharmaceuticals-phas-hits-new-52-week-low-at-4-72.html.
About PhaseBio Pharmaceuticals (NASDAQ:PHAS)
PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.
Featured Article: Balance Sheet
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.